As of 2025-05-18, the EV/EBITDA ratio of Madrigal Pharmaceuticals Inc (MDGL) is -14.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MDGL's latest enterprise value is 6,343.72 mil USD. MDGL's TTM EBITDA according to its financial statements is -423.84 mil USD. Dividing these 2 quantities gives us the above MDGL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 13.7x | 13.5x |
| Forward P/E multiples | 15.3x - 18.4x | 17.6x |
| Fair Price | (286.14) - (257.12) | (291.67) |
| Upside | -198.3% - -188.4% | -200.2% |
| Date | EV/EBITDA |
| 2025-05-14 | -14.54 |
| 2025-05-13 | -15.20 |
| 2025-05-12 | -15.48 |
| 2025-05-09 | -15.16 |
| 2025-05-08 | -15.42 |
| 2025-05-07 | -15.38 |
| 2025-05-06 | -15.19 |
| 2025-05-05 | -15.77 |
| 2025-05-02 | -16.25 |
| 2025-05-01 | -16.89 |
| 2025-04-30 | -17.22 |
| 2025-04-29 | -17.58 |
| 2025-04-28 | -17.08 |
| 2025-04-25 | -16.84 |
| 2025-04-24 | -16.48 |
| 2025-04-23 | -15.90 |
| 2025-04-22 | -15.58 |
| 2025-04-21 | -15.18 |
| 2025-04-17 | -15.53 |
| 2025-04-16 | -15.85 |
| 2025-04-15 | -16.55 |
| 2025-04-14 | -16.61 |
| 2025-04-11 | -16.34 |
| 2025-04-10 | -15.83 |
| 2025-04-09 | -16.17 |
| 2025-04-08 | -15.59 |
| 2025-04-07 | -15.99 |
| 2025-04-04 | -16.19 |
| 2025-04-03 | -16.86 |
| 2025-04-02 | -17.25 |
| 2025-04-01 | -16.70 |
| 2025-03-31 | -17.08 |
| 2025-03-28 | -16.90 |
| 2025-03-27 | -17.39 |
| 2025-03-26 | -17.21 |
| 2025-03-25 | -17.71 |
| 2025-03-24 | -17.87 |
| 2025-03-21 | -17.62 |
| 2025-03-20 | -17.28 |
| 2025-03-19 | -17.58 |
| 2025-03-18 | -17.46 |
| 2025-03-17 | -17.66 |
| 2025-03-14 | -17.97 |
| 2025-03-13 | -16.65 |
| 2025-03-12 | -16.87 |
| 2025-03-11 | -17.29 |
| 2025-03-10 | -16.97 |
| 2025-03-07 | -17.09 |
| 2025-03-06 | -16.95 |
| 2025-03-05 | -17.92 |